MX2024004393A - Nuevo anticuerpo monoclonal nav1.7. - Google Patents

Nuevo anticuerpo monoclonal nav1.7.

Info

Publication number
MX2024004393A
MX2024004393A MX2024004393A MX2024004393A MX2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
novel
chain variable
variable region
specific
Prior art date
Application number
MX2024004393A
Other languages
English (en)
Spanish (es)
Inventor
Tatsuya Takahashi
Junji Onoda
Mai YOSHIKAWA
Erika KASAI
Daiki Nakamori
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2024004393A publication Critical patent/MX2024004393A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024004393A 2021-11-01 2022-10-31 Nuevo anticuerpo monoclonal nav1.7. MX2024004393A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021178982 2021-11-01
JP2022005967 2022-01-18
PCT/JP2022/040580 WO2023074888A1 (ja) 2021-11-01 2022-10-31 新規なNav1.7モノクローナル抗体

Publications (1)

Publication Number Publication Date
MX2024004393A true MX2024004393A (es) 2024-04-30

Family

ID=86159498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004393A MX2024004393A (es) 2021-11-01 2022-10-31 Nuevo anticuerpo monoclonal nav1.7.

Country Status (12)

Country Link
US (1) US20250163145A1 (https=)
EP (1) EP4428239A4 (https=)
JP (1) JP7457880B2 (https=)
KR (1) KR102753603B1 (https=)
AU (1) AU2022377536B2 (https=)
CA (1) CA3236404A1 (https=)
CO (1) CO2024003915A2 (https=)
IL (1) IL311683B2 (https=)
MX (1) MX2024004393A (https=)
MY (1) MY206945A (https=)
TW (1) TWI867354B (https=)
WO (1) WO2023074888A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なNav1.7モノクローナル抗体を含む医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214973B1 (en) 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
MX2015010749A (es) 2013-03-14 2015-11-30 Regeneron Pharma Anticuerpos humanos para nav1.7.
JP2016529909A (ja) * 2013-09-05 2016-09-29 デューク ユニバーシティ Nav1.7抗体及び前記抗体を使用する方法
GB2517953A (en) 2013-09-05 2015-03-11 Argen X Bv Antibodies to complex targets
JPWO2019230856A1 (ja) * 2018-05-31 2021-06-24 塩野義製薬株式会社 Nav1.7モノクローナル抗体
US20240002497A1 (en) 2020-11-19 2024-01-04 Merck Sharp & Dohme Llc Nav1.7 binders
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なNav1.7モノクローナル抗体を含む医薬組成物

Also Published As

Publication number Publication date
KR102753603B1 (ko) 2025-01-13
CA3236404A1 (en) 2023-05-04
JPWO2023074888A1 (https=) 2023-05-04
WO2023074888A1 (ja) 2023-05-04
TWI867354B (zh) 2024-12-21
EP4428239A4 (en) 2025-10-29
IL311683B2 (en) 2026-04-01
JP7457880B2 (ja) 2024-03-28
IL311683B1 (en) 2025-12-01
KR20240099394A (ko) 2024-06-28
MY206945A (en) 2025-01-21
TW202325739A (zh) 2023-07-01
AU2022377536A1 (en) 2024-04-11
EP4428239A1 (en) 2024-09-11
AU2022377536B2 (en) 2024-10-24
US20250163145A1 (en) 2025-05-22
IL311683A (en) 2024-05-01
CO2024003915A2 (es) 2024-04-18

Similar Documents

Publication Publication Date Title
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
ZA202006317B (en) Monoclonal antibody of nerve growth factor and encoding gene and use thereof
PH12022550211A1 (en) Anti-pd-1 antibody and medical use thereof
NZ738979A (en) Pd-1 antibodies
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
BR112023004830A2 (pt) Métodos para tratamento de mieloma múltiplo
PE20221337A1 (es) Anticuerpos trem2 y usos de estos
ZA202101258B (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
MX2020012678A (es) Anticuerpo monoclonal contra nav1.7.
NZ594682A (en) Fully human antibodies specific to cadm1
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
NZ755083A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
JOP20220309A1 (ar) أجسام مضادة تستهدف معقد يشتمل على hla-i ومولد ضد جديد غير تقليدية وطرق استخدامها
MX2021001516A (es) Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
ZA202305217B (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
PE20211296A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
ZA202400787B (en) Pharmaceutical composition and use
AR112563A1 (es) Anticuerpos monoclonales anti-sortilina útiles en la corrección de un nivel deficiente de progranulina (pgrn)
MX2024004393A (es) Nuevo anticuerpo monoclonal nav1.7.
ZA202205288B (en) Humanized antibody and method for using the same
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
ZA202202380B (en) Anti-human p40 protein domain antibody and use thereof
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
PE20231953A1 (es) Anticuerpos multiespecificos y combinaciones de anticuerpos